Final Glance: Biotechnology companies
AP - 2 hrs 46 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Amgen's FOCUS Study on Multiple Myeloma Drug Kyprolis Fails - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 4:20PM CDT
Amgen (AMGN) suffered a major setback when its phase III study, FOCUS on multiple myeloma treatment, Kyprolis did not meet its primary endpoint.
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 2.53%
Comtex SmarTrend(R) - Thu Aug 14, 3:38PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $94.24 to a high of $96.37. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $94.61 on volume of 12.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Midday Glance: Biotechnology companies
AP - Thu Aug 14, 12:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Should Gilead Sciences (GILD) Be in Your Portfolio? - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Thu Aug 14, 12:00PM CDT
A closer look at Gilead Sciences (GILD) stock and if it should be in your portfolio.
Biotech, Social Media Stocks Are Less Frothy Than Janet Yellen Thinks
at The Street - Thu Aug 14, 11:34AM CDT
A month after Fed Chair Janet Yellen's comments, ETFs covering both groups are pushing towards new highs on strong fundamental backdrops.
Early Glance: Biotechnology companies
AP - Thu Aug 14, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Stock Market News for August 14, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:10AM CDT
Benchmarks ended in the green as gains in biotech stocks offset discouraging retail sales numbers
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $94.61
Comtex SmarTrend(R) - Thu Aug 14, 9:00AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $93.98 today and have reached the first resistance level of $94.61. Investors may be interested in a cross of the next upside pivot targets of $95.25 and $96.52.
Zacks.com featured expert Kevin Matras highlights: Gilead Sciences, LyondellBasell, Magna Int'l, RF Micro Devices and United Continental Holdings.
PR Newswire - Thu Aug 14, 8:30AM CDT
Stocks in this week's article include: Gilead Sciences (NASDAQ: GILD - Free Report), LyondellBasell (NYSE: LYB - Free Report), Magna Int'l (NYSE: MGA - Free Report), RF Micro Devices (NASDAQ: RFMD - Free Report) and United Continental Holdings (NYSE: UAL - Free Report). Kevin Matras talks about a stock's Earnings Yield and how to use it.
Strong Earnings Season Winding Down - Earnings Trends
Sheraz Mian - Zacks Investment Research - Thu Aug 14, 2:19AM CDT
Strong Earnings Season Winding Down - Earnings Trends
Strong Earnings Season Winding Down - Earnings Outlook
Sheraz Mian - Zacks Investment Research - Thu Aug 14, 2:19AM CDT
Strong Earnings Season Winding Down - Earnings Outlook
Dendreon Down on Default Risk, Reports Narrower Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 1:37PM CDT
Shares of Dendreon Corporation (DNDN) were down significantly after the company warned that it will not be able to repay or refinance its notes due 2016.
BioDelivery Sciences Q2 Loss Narrows, Up on Solid Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 12:02PM CDT
Shares of BioDelivery Sciences International, Inc. (BDSI) jumped 7.58 % after the company reported its second-quarter 2014 results.
Pharmacyclics Has Edge Over Blood Cancer Competitors
at The Street - Wed Aug 13, 9:49AM CDT
Imbruvica will be an important part of the treatment landscape for blood cancers.
Intercept Pharmaceuticals Posts Earnings, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 9:40AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) reported earnings of $1.51 per share in the quarter comparing favorably with the Zacks Consensus estimate of a loss of $1.10.
Gilead Sciences,Melco Crown Entertainment,Banco Santander, BarclaysandDeutsche Bankhighlighted as Zacks Bull and Bear of the Day
PR Newswire - Wed Aug 13, 8:30AM CDT
Zacks Equity Research highlights Gilead Sciences (Nasdaq:GILD-Free Report) as the Bull of the Day and Melco Crown Entertainment (Nasdaq:MPEL-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis onBanco Santander, S.A. (NYSE:SAN-Free Report), Barclays PLC (NYSE:BCS-Free Report) and Deutsche Bank AG (NYSE
Celladon (CLDN) Falls: Stock Goes Down 6.2% - Tale of the Tape
Zacks Research Stuff - Zacks Investment Research - Wed Aug 13, 7:30AM CDT
Celladon stock fell over 6% last trading session, continuing its recent downtrend